Generic Name and Formulations:
Verteporfin 15mg/vial; pwd for IV inj after reconstitution and dilution.
Bausch Health Companies Inc.
Indications for VISUDYNE:
Treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis.
See literature regarding lesion size determination, spot size determination, light administration, and concurrent bilateral treatment. Use largest arm vein possible for inj; avoid small veins of the back of the hand. Give by IV infusion over 10 minutes at a rate of 3mL/min. Usual dose: 6mg/m2. After infusion, the second step is activation of verteporfin with light from a nonthermal diode laser. Reevaluate every 3 months and if choroidal neovascular leakage is detected on fluorescein angiography, therapy should be repeated.
Avoid sunlight or bright indoor light exposure of skin or eyes for 5 days after injection. If severe decrease of vision of ≥4 lines within 1 week after treatment, do no retreat; wait until vision recovers to pretreatment levels. Use of incompatible lasers could result in incomplete treatment. Stop infusion immediately if extravasation occurs; treat. Moderate to severe hepatic impairment. Biliary obstruction. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Calcium channel blockers, polymyxin B, radiation therapy: may enhance rate of verteporfin uptake by vascular endothelium. Increased risk of photosensitivity reactions with concomitant photosensitizing agents (eg, tetracyclines, sulfonamides, phenothiazines, sulfonylureas, thiazides, griseofulvin). May be antagonized by dimethyl sulfoxide, β-carotene, ethanol, formate, mannitol, drugs that decrease clotting, vasoconstriction, or platelet aggregation (eg, thromboxane A2 inhibitors).
Inj site reactions (eg, pain, edema, inflammation, extravasation, rash, hemorrhage, discoloration), visual disturbances (eg, blurred vision, flashes of light, decreased visual acuity, visual field defects including scotoma); others.
Neurology Advisor Articles
- Higher Levels of Cholesterol May Protect Men From Parkinson Disease
- Ajovy Injection Approved for Migraine Prevention in Adults
- Chronic Pain May Be Contributor to Suicide
- FDA Approves Tiglutik for the Treatment of Amyotrophic Lateral Sclerosis
- Natalizumab Improves Cognitive Function in Multiple Sclerosis
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- New 15-Item Dyspnea-ALS-Score Assesses Dyspnea in ALS
- CDC: About One in Five U.S. Adults Have Chronic Pain
- Fingolimod Cuts Multiple Sclerosis Relapses in Pediatric Patients
- Gains in Insurance Coverage Seen for Lesbian, Gay, Bisexual Adults
- Brivaracetam Effective for Reducing Seizures in Patients with Epileptic Encephalopathies